Share Price and Basic Stock Data
Last Updated: March 8, 2025, 10:07 am
| PEG Ratio | 1.95 |
|---|
Competitors of TTK Healthcare Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| MPS Pharmaa Ltd | 6.71 Cr. | 3.51 | 4.33/3.05 | 0.80 | 0.00 % | 9.15 % | 34.9 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 2,663 Cr. | 244 | 390/192 | 50.6 | 20.5 | 0.27 % | 45.0 % | 33.8 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 53.1 Cr. | 71.5 | 94.9/32.1 | 18.0 | 11.9 | 0.00 % | 9.72 % | 3.44 % | 10.0 |
| Gujarat Inject (Kerala) Ltd | 38.0 Cr. | 26.0 | 29.0/8.74 | 38.8 | 6.64 | 0.00 % | 2.65 % | 2.08 % | 10.0 |
| Godavari Drugs Ltd | 70.4 Cr. | 93.5 | 155/79.0 | 11.4 | 55.4 | 0.00 % | 14.4 % | 15.5 % | 10.0 |
| Industry Average | 17,255.37 Cr | 1,081.84 | 42.42 | 185.80 | 0.37% | 16.00% | 16.32% | 6.27 |
Quarterly Result
| Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 159 | 159 | 193 | 170 | 183 | 180 | 202 | 186 | 184 | 181 | 208 | 198 | 205 |
| Expenses | 150 | 154 | 189 | 166 | 174 | 165 | 192 | 176 | 179 | 169 | 201 | 190 | 197 |
| Operating Profit | 8 | 5 | 4 | 4 | 8 | 15 | 10 | 10 | 5 | 12 | 7 | 8 | 8 |
| OPM % | 5% | 3% | 2% | 2% | 5% | 8% | 5% | 5% | 3% | 7% | 3% | 4% | 4% |
| Other Income | 10 | 12 | 606 | 13 | 12 | 12 | 15 | 16 | 16 | 16 | 37 | 18 | 18 |
| Interest | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
| Profit before tax | 14 | 12 | 604 | 13 | 16 | 23 | 21 | 22 | 18 | 24 | 41 | 23 | 23 |
| Tax % | 15% | 13% | 1% | 23% | 26% | 27% | 24% | 26% | 27% | 25% | 23% | 26% | 26% |
| Net Profit | 12 | 11 | 601 | 10 | 12 | 17 | 16 | 16 | 13 | 18 | 32 | 17 | 17 |
| EPS in Rs | 8.61 | 7.52 | 425.23 | 7.01 | 8.49 | 11.99 | 11.09 | 11.33 | 9.12 | 12.93 | 22.35 | 12.17 | 11.84 |
Last Updated: February 28, 2025, 4:29 pm
Below is a detailed analysis of the quarterly data for TTK Healthcare Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:
- For Sales, as of Dec 2024, the value is ₹205.00 Cr.. The value appears strong and on an upward trend. It has increased from 198.00 Cr. (Sep 2024) to ₹205.00 Cr., marking an increase of ₹7.00 Cr..
- For Expenses, as of Dec 2024, the value is ₹197.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 190.00 Cr. (Sep 2024) to ₹197.00 Cr., marking an increase of ₹7.00 Cr..
- For Operating Profit, as of Dec 2024, the value is ₹8.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 8.00 Cr..
- For OPM %, as of Dec 2024, the value is 4.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 4.00%.
- For Other Income, as of Dec 2024, the value is ₹18.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 18.00 Cr..
- For Interest, as of Dec 2024, the value is ₹1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 1.00 Cr..
- For Depreciation, as of Dec 2024, the value is ₹2.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 2.00 Cr..
- For Profit before tax, as of Dec 2024, the value is ₹23.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 23.00 Cr..
- For Tax %, as of Dec 2024, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 26.00%.
- For Net Profit, as of Dec 2024, the value is ₹17.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 17.00 Cr..
- For EPS in Rs, as of Dec 2024, the value is 11.84. The value appears to be declining and may need further review. It has decreased from ₹12.17 (Sep 2024) to 11.84, marking a decrease of ₹0.33.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: March 6, 2025, 2:32 pm
| Metric | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 382 | 416 | 483 | 519 | 528 | 578 | 628 | 646 | 476 | 599 | 725 | 753 | 792 |
| Expenses | 362 | 396 | 453 | 478 | 489 | 535 | 578 | 617 | 457 | 577 | 694 | 715 | 757 |
| Operating Profit | 20 | 20 | 30 | 40 | 38 | 43 | 50 | 28 | 19 | 22 | 31 | 37 | 35 |
| OPM % | 5% | 5% | 6% | 8% | 7% | 7% | 8% | 4% | 4% | 4% | 4% | 5% | 4% |
| Other Income | 7 | 6 | 7 | 6 | 6 | 8 | 8 | 9 | 28 | 42 | 643 | 63 | 88 |
| Interest | 3 | 3 | 4 | 3 | 3 | 5 | 3 | 3 | 2 | 3 | 5 | 3 | 3 |
| Depreciation | 3 | 3 | 6 | 7 | 12 | 15 | 15 | 14 | 13 | 13 | 13 | 13 | 9 |
| Profit before tax | 22 | 20 | 26 | 36 | 29 | 30 | 39 | 19 | 32 | 48 | 657 | 84 | 111 |
| Tax % | 34% | 37% | 39% | 36% | 36% | 40% | 38% | 37% | -44% | 13% | 3% | 25% | |
| Net Profit | 14 | 12 | 16 | 23 | 19 | 18 | 24 | 12 | 46 | 42 | 640 | 63 | 84 |
| EPS in Rs | 18.28 | 15.95 | 20.81 | 29.19 | 24.13 | 12.86 | 17.25 | 8.72 | 32.87 | 29.43 | 452.72 | 44.47 | 59.29 |
| Dividend Payout % | 22% | 25% | 22% | 17% | 21% | 39% | 29% | 34% | 18% | 34% | 2% | 22% |
YoY Net Profit Growth
| Year | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -14.29% | 33.33% | 43.75% | -17.39% | -5.26% | 33.33% | -50.00% | 283.33% | -8.70% | 1423.81% | -90.16% |
| Change in YoY Net Profit Growth (%) | 0.00% | 47.62% | 10.42% | -61.14% | 12.13% | 38.60% | -83.33% | 333.33% | -292.03% | 1432.51% | -1513.97% |
TTK Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: November 14, 2024, 6:40 pm
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | 90 | 99 | 110 | 128 | 150 | 219 | 237 | 235 | 281 | 316 | 939 | 987 | 1,025 |
| Borrowings | 22 | 32 | 42 | 38 | 23 | 47 | 29 | 30 | 19 | 22 | 27 | 23 | 31 |
| Other Liabilities | 89 | 102 | 115 | 128 | 104 | 127 | 136 | 152 | 180 | 207 | 189 | 177 | 197 |
| Total Liabilities | 209 | 240 | 275 | 303 | 285 | 407 | 416 | 431 | 494 | 559 | 1,170 | 1,201 | 1,267 |
| Fixed Assets | 43 | 54 | 52 | 106 | 99 | 110 | 98 | 89 | 85 | 80 | 71 | 75 | 74 |
| CWIP | 0 | 2 | 46 | 1 | 0 | 1 | 2 | 9 | 0 | 0 | 3 | 1 | 5 |
| Investments | 1 | 0 | 0 | 10 | 9 | 9 | 13 | 9 | 13 | 15 | 13 | 13 | 16 |
| Other Assets | 165 | 184 | 177 | 185 | 177 | 288 | 304 | 325 | 395 | 463 | 1,083 | 1,112 | 1,171 |
| Total Assets | 209 | 240 | 275 | 303 | 285 | 407 | 416 | 431 | 494 | 559 | 1,170 | 1,201 | 1,267 |
Below is a detailed analysis of the balance sheet data for TTK Healthcare Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2024, the value is ₹14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹14.00 Cr..
- For Reserves, as of Sep 2024, the value is ₹1,025.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹987.00 Cr. (Mar 2024) to ₹1,025.00 Cr., marking an increase of 38.00 Cr..
- For Borrowings, as of Sep 2024, the value is ₹31.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹23.00 Cr. (Mar 2024) to ₹31.00 Cr., marking an increase of 8.00 Cr..
- For Other Liabilities, as of Sep 2024, the value is ₹197.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹177.00 Cr. (Mar 2024) to ₹197.00 Cr., marking an increase of 20.00 Cr..
- For Total Liabilities, as of Sep 2024, the value is ₹1,267.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹1,201.00 Cr. (Mar 2024) to ₹1,267.00 Cr., marking an increase of 66.00 Cr..
- For Fixed Assets, as of Sep 2024, the value is ₹74.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹75.00 Cr. (Mar 2024) to ₹74.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Sep 2024, the value is ₹5.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1.00 Cr. (Mar 2024) to ₹5.00 Cr., marking an increase of 4.00 Cr..
- For Investments, as of Sep 2024, the value is ₹16.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹13.00 Cr. (Mar 2024) to ₹16.00 Cr., marking an increase of 3.00 Cr..
- For Other Assets, as of Sep 2024, the value is ₹1,171.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,112.00 Cr. (Mar 2024) to ₹1,171.00 Cr., marking an increase of 59.00 Cr..
- For Total Assets, as of Sep 2024, the value is ₹1,267.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,201.00 Cr. (Mar 2024) to ₹1,267.00 Cr., marking an increase of 66.00 Cr..
Notably, the Reserves (₹1,025.00 Cr.) exceed the Borrowings (31.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
No data available for this post.
Free Cash Flow
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.00 | -12.00 | -12.00 | 2.00 | 15.00 | -4.00 | 21.00 | -2.00 | 0.00 | 0.00 | 4.00 | 14.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 34 | 34 | 34 | 33 | 24 | 35 | 47 | 43 | 46 | 33 | 46 | 42 |
| Inventory Days | 52 | 64 | 62 | 66 | 65 | 80 | 77 | 101 | 123 | 102 | 89 | 105 |
| Days Payable | 55 | 56 | 50 | 53 | 100 | 130 | 101 | 121 | 170 | 134 | 116 | 110 |
| Cash Conversion Cycle | 31 | 41 | 46 | 46 | -11 | -16 | 22 | 23 | -2 | 1 | 19 | 36 |
| Working Capital Days | -8 | -12 | -14 | -22 | -9 | -1 | 10 | 13 | -18 | -15 | 17 | 62 |
| ROCE % | 21% | 17% | 20% | 23% | 18% | 15% | 15% | 8% | 6% | 8% | 10% | 9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Axis ELSS Tax Saver Fund | 172,386 | 0.08 | 25.52 | 172,386 | 2025-03-06 | 0% |
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 44.47 | 452.72 | 29.43 | 32.87 | 8.72 |
| Diluted EPS (Rs.) | 44.47 | 452.72 | 29.43 | 32.87 | 8.72 |
| Cash EPS (Rs.) | 53.71 | 461.79 | 38.34 | 42.08 | 18.89 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 705.23 | 671.59 | 230.16 | 205.40 | 173.09 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 708.35 | 674.71 | 233.28 | 208.52 | 176.21 |
| Dividend / Share (Rs.) | 10.00 | 10.00 | 10.00 | 6.00 | 3.00 |
| Revenue From Operations / Share (Rs.) | 532.75 | 513.16 | 424.08 | 336.91 | 457.01 |
| PBDIT / Share (Rs.) | 70.72 | 56.39 | 27.01 | 20.70 | 26.23 |
| PBIT / Share (Rs.) | 61.48 | 47.33 | 18.11 | 11.49 | 16.06 |
| PBT / Share (Rs.) | 59.53 | 43.62 | 17.58 | 16.01 | 13.75 |
| Net Profit / Share (Rs.) | 44.47 | 452.72 | 29.43 | 32.87 | 8.72 |
| PBDIT Margin (%) | 13.27 | 10.98 | 6.36 | 6.14 | 5.74 |
| PBIT Margin (%) | 11.54 | 9.22 | 4.26 | 3.41 | 3.51 |
| PBT Margin (%) | 11.17 | 8.50 | 4.14 | 4.75 | 3.00 |
| Net Profit Margin (%) | 8.34 | 88.22 | 6.94 | 9.75 | 1.90 |
| Return on Networth / Equity (%) | 6.30 | 67.41 | 12.78 | 16.00 | 5.03 |
| Return on Capital Employeed (%) | 8.64 | 6.97 | 7.56 | 5.31 | 8.73 |
| Return On Assets (%) | 5.23 | 54.67 | 7.44 | 9.39 | 2.85 |
| Total Debt / Equity (X) | 0.02 | 0.02 | 0.06 | 0.06 | 0.11 |
| Asset Turnover Ratio (%) | 0.63 | 0.83 | 1.14 | 1.03 | 1.52 |
| Current Ratio (X) | 5.50 | 5.06 | 2.03 | 1.99 | 1.74 |
| Quick Ratio (X) | 5.01 | 4.66 | 1.68 | 1.61 | 1.32 |
| Inventory Turnover Ratio (X) | 1.91 | 2.23 | 1.92 | 1.38 | 1.64 |
| Dividend Payout Ratio (NP) (%) | 22.48 | 2.20 | 20.38 | 9.12 | 57.34 |
| Dividend Payout Ratio (CP) (%) | 18.61 | 2.16 | 15.65 | 7.12 | 26.46 |
| Earning Retention Ratio (%) | 77.52 | 97.80 | 79.62 | 90.88 | 42.66 |
| Cash Earning Retention Ratio (%) | 81.39 | 97.84 | 84.35 | 92.88 | 73.54 |
| Interest Coverage Ratio (X) | 36.27 | 15.21 | 11.79 | 17.10 | 11.34 |
| Interest Coverage Ratio (Post Tax) (X) | 23.81 | 9.53 | 5.95 | 17.77 | 4.77 |
| Enterprise Value (Cr.) | 1342.13 | 639.44 | 918.42 | 488.79 | 358.06 |
| EV / Net Operating Revenue (X) | 1.78 | 0.88 | 1.53 | 1.03 | 0.55 |
| EV / EBITDA (X) | 13.43 | 8.03 | 24.06 | 16.71 | 9.66 |
| MarketCap / Net Operating Revenue (X) | 2.78 | 2.01 | 1.96 | 1.47 | 0.71 |
| Retention Ratios (%) | 77.51 | 97.79 | 79.61 | 90.87 | 42.65 |
| Price / BV (X) | 2.10 | 1.54 | 3.60 | 2.41 | 1.89 |
| Price / Net Operating Revenue (X) | 2.78 | 2.01 | 1.96 | 1.47 | 0.71 |
| EarningsYield | 0.02 | 0.43 | 0.03 | 0.06 | 0.02 |
After reviewing the key financial ratios for TTK Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 44.47. This value is within the healthy range. It has decreased from 452.72 (Mar 23) to 44.47, marking a decrease of 408.25.
- For Diluted EPS (Rs.), as of Mar 24, the value is 44.47. This value is within the healthy range. It has decreased from 452.72 (Mar 23) to 44.47, marking a decrease of 408.25.
- For Cash EPS (Rs.), as of Mar 24, the value is 53.71. This value is within the healthy range. It has decreased from 461.79 (Mar 23) to 53.71, marking a decrease of 408.08.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 705.23. It has increased from 671.59 (Mar 23) to 705.23, marking an increase of 33.64.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 708.35. It has increased from 674.71 (Mar 23) to 708.35, marking an increase of 33.64.
- For Dividend / Share (Rs.), as of Mar 24, the value is 10.00. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 532.75. It has increased from 513.16 (Mar 23) to 532.75, marking an increase of 19.59.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 70.72. This value is within the healthy range. It has increased from 56.39 (Mar 23) to 70.72, marking an increase of 14.33.
- For PBIT / Share (Rs.), as of Mar 24, the value is 61.48. This value is within the healthy range. It has increased from 47.33 (Mar 23) to 61.48, marking an increase of 14.15.
- For PBT / Share (Rs.), as of Mar 24, the value is 59.53. This value is within the healthy range. It has increased from 43.62 (Mar 23) to 59.53, marking an increase of 15.91.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 44.47. This value is within the healthy range. It has decreased from 452.72 (Mar 23) to 44.47, marking a decrease of 408.25.
- For PBDIT Margin (%), as of Mar 24, the value is 13.27. This value is within the healthy range. It has increased from 10.98 (Mar 23) to 13.27, marking an increase of 2.29.
- For PBIT Margin (%), as of Mar 24, the value is 11.54. This value is within the healthy range. It has increased from 9.22 (Mar 23) to 11.54, marking an increase of 2.32.
- For PBT Margin (%), as of Mar 24, the value is 11.17. This value is within the healthy range. It has increased from 8.50 (Mar 23) to 11.17, marking an increase of 2.67.
- For Net Profit Margin (%), as of Mar 24, the value is 8.34. This value is within the healthy range. It has decreased from 88.22 (Mar 23) to 8.34, marking a decrease of 79.88.
- For Return on Networth / Equity (%), as of Mar 24, the value is 6.30. This value is below the healthy minimum of 15. It has decreased from 67.41 (Mar 23) to 6.30, marking a decrease of 61.11.
- For Return on Capital Employeed (%), as of Mar 24, the value is 8.64. This value is below the healthy minimum of 10. It has increased from 6.97 (Mar 23) to 8.64, marking an increase of 1.67.
- For Return On Assets (%), as of Mar 24, the value is 5.23. This value is within the healthy range. It has decreased from 54.67 (Mar 23) to 5.23, marking a decrease of 49.44.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.02. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 0.02.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.63. It has decreased from 0.83 (Mar 23) to 0.63, marking a decrease of 0.20.
- For Current Ratio (X), as of Mar 24, the value is 5.50. This value exceeds the healthy maximum of 3. It has increased from 5.06 (Mar 23) to 5.50, marking an increase of 0.44.
- For Quick Ratio (X), as of Mar 24, the value is 5.01. This value exceeds the healthy maximum of 2. It has increased from 4.66 (Mar 23) to 5.01, marking an increase of 0.35.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.91. This value is below the healthy minimum of 4. It has decreased from 2.23 (Mar 23) to 1.91, marking a decrease of 0.32.
- For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 22.48. This value is within the healthy range. It has increased from 2.20 (Mar 23) to 22.48, marking an increase of 20.28.
- For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 18.61. This value is below the healthy minimum of 20. It has increased from 2.16 (Mar 23) to 18.61, marking an increase of 16.45.
- For Earning Retention Ratio (%), as of Mar 24, the value is 77.52. This value exceeds the healthy maximum of 70. It has decreased from 97.80 (Mar 23) to 77.52, marking a decrease of 20.28.
- For Cash Earning Retention Ratio (%), as of Mar 24, the value is 81.39. This value exceeds the healthy maximum of 70. It has decreased from 97.84 (Mar 23) to 81.39, marking a decrease of 16.45.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 36.27. This value is within the healthy range. It has increased from 15.21 (Mar 23) to 36.27, marking an increase of 21.06.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 23.81. This value is within the healthy range. It has increased from 9.53 (Mar 23) to 23.81, marking an increase of 14.28.
- For Enterprise Value (Cr.), as of Mar 24, the value is 1,342.13. It has increased from 639.44 (Mar 23) to 1,342.13, marking an increase of 702.69.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.78. This value is within the healthy range. It has increased from 0.88 (Mar 23) to 1.78, marking an increase of 0.90.
- For EV / EBITDA (X), as of Mar 24, the value is 13.43. This value is within the healthy range. It has increased from 8.03 (Mar 23) to 13.43, marking an increase of 5.40.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 2.78. This value is within the healthy range. It has increased from 2.01 (Mar 23) to 2.78, marking an increase of 0.77.
- For Retention Ratios (%), as of Mar 24, the value is 77.51. This value exceeds the healthy maximum of 70. It has decreased from 97.79 (Mar 23) to 77.51, marking a decrease of 20.28.
- For Price / BV (X), as of Mar 24, the value is 2.10. This value is within the healthy range. It has increased from 1.54 (Mar 23) to 2.10, marking an increase of 0.56.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 2.78. This value is within the healthy range. It has increased from 2.01 (Mar 23) to 2.78, marking an increase of 0.77.
- For EarningsYield, as of Mar 24, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.43 (Mar 23) to 0.02, marking a decrease of 0.41.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in TTK Healthcare Ltd:
- Net Profit Margin: 8.34%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.64% (Industry Average ROCE: 16%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.3% (Industry Average ROE: 16.32%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 23.81
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 5.01
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 24.4 (Industry average Stock P/E: 42.42)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.02
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.34%
About the Company - Qualitative Analysis
TTK Healthcare Ltd. is a Public Limited Listed company incorporated on 21/05/1958 and has its registered office in the State of Tamil Nadu, India. Company's Corporate Identification Number(CIN) is L24231TN1958PLC003647 and registration number is 003647. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 752.79 Cr. and Equity Capital is Rs. 14.13 Cr. for the Year ended 31/03/2024.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | No 6, Cathedral Road, Chennai (Madras) Tamil Nadu 600086 | info@ttkhealthcare.com http://www.ttkhealthcare.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. T T Raghunathan | Executive Chairman |
| Mr. S Kalyanaraman | Whole Time Director |
| Dr. T T Mukund | Director |
| Mr. R K Tulshan | Director |
| Mr. K Shankaran | Director |
| Dr.(Mrs.) Vandana R Walvekar | Independent Director |
| Mr. Girish Rao | Independent Director |
| Mr. S Balasubramanian | Independent Director |
| Mr. V Ranganathan | Independent Director |
| Mr. N Ramesh Rajan | Independent Director |
FAQ
What is the latest intrinsic value of TTK Healthcare Ltd?
The latest intrinsic value of TTK Healthcare Ltd as on 12 March 2025 is ₹930.27, which is 21.43% lower than the current market price of 1,184.00, indicating the stock is overvalued by 21.43%. The intrinsic value of TTK Healthcare Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹1,673 Cr. and recorded a high/low of ₹1,923/1,060 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹1,025 Cr and total liabilities of ₹1,267 Cr.
What is the Market Cap of TTK Healthcare Ltd?
The Market Cap of TTK Healthcare Ltd is 1,673 Cr..
What is the current Stock Price of TTK Healthcare Ltd as on 12 March 2025?
The current stock price of TTK Healthcare Ltd as on 12 March 2025 is ₹1,184.
What is the High / Low of TTK Healthcare Ltd stocks in FY 2024-2025?
In FY 2024-2025, the High / Low of TTK Healthcare Ltd stocks is ₹1,923/1,060.
What is the Stock P/E of TTK Healthcare Ltd?
The Stock P/E of TTK Healthcare Ltd is 24.4.
What is the Book Value of TTK Healthcare Ltd?
The Book Value of TTK Healthcare Ltd is 735.
What is the Dividend Yield of TTK Healthcare Ltd?
The Dividend Yield of TTK Healthcare Ltd is 0.84 %.
What is the ROCE of TTK Healthcare Ltd?
The ROCE of TTK Healthcare Ltd is 8.67 %.
What is the ROE of TTK Healthcare Ltd?
The ROE of TTK Healthcare Ltd is 6.43 %.
What is the Face Value of TTK Healthcare Ltd?
The Face Value of TTK Healthcare Ltd is 10.0.